APA (7th ed.) Citation

JH, K. (2024). Intraocular inflammation as a major adverse event of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: From clinical trials to real-world practice. Expert opinion on drug safety, 23(6), 659. https://doi.org/10.1080/14740338.2024.2351468

Chicago Style (17th ed.) Citation

JH, Kim. "Intraocular Inflammation as a Major Adverse Event of Anti-vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration: From Clinical Trials to Real-world Practice." Expert Opinion on Drug Safety 23, no. 6 (2024): 659. https://doi.org/10.1080/14740338.2024.2351468.

MLA (9th ed.) Citation

JH, Kim. "Intraocular Inflammation as a Major Adverse Event of Anti-vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration: From Clinical Trials to Real-world Practice." Expert Opinion on Drug Safety, vol. 23, no. 6, 2024, p. 659, https://doi.org/10.1080/14740338.2024.2351468.